Table 2 Population pharmacokinetic parameter estimates and relative standard errors (RSE) for the final raltegravir model (n = 349 individuals). Of the covariates tested none fulfilled the statistical criteria to remain in the model.

From: Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study

Parameter

Estimate (RSE%)

Fixed effects

  CL/F (L/h)

55.8 (4.1)

  Vc/F (L)

194 (6.5)

  Q/F (L/h)

13.0 (4.0)

  Vp/F (L)

117 (0.6)

  ka (h−1)

1.12 (13.0)

Random effects

  IIV CL/F (%)

62.7 (12.1)

Residual error

  Proportional (%)

69.9 (7.0)

  1. RSE = (SEESTIMATE/ESTIMATE) × 100.
  2. CL/F apparent oral clearance, Vc/F apparent volume of distribution of the central compartment, Q/F  intercompartmental clearance, Vp/F volume of the peripheral compartment, ka absorption rate constant IIV, interindividual variability.
Back to article page